FY2029 Earnings Estimate for ACRS Issued By Leerink Partnrs

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Leerink Partnrs issued their FY2029 earnings estimates for Aclaris Therapeutics in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith anticipates that the biotechnology company will earn ($1.02) per share for the year. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.86) per share.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its earnings results on Wednesday, November 6th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.03). The company had revenue of $4.35 million for the quarter, compared to analyst estimates of $8.31 million. Aclaris Therapeutics had a negative return on equity of 40.26% and a negative net margin of 136.65%.

Other equities analysts have also issued research reports about the stock. BTIG Research raised shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 price target for the company in a report on Tuesday, November 19th. StockNews.com lowered Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 31st. Piper Sandler raised Aclaris Therapeutics from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $3.00 to $13.00 in a research note on Monday, November 18th. HC Wainwright upgraded shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $20.00 price target for the company in a report on Monday, December 23rd. Finally, Leerink Partners upgraded shares of Aclaris Therapeutics from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $2.00 to $7.00 in a report on Tuesday, November 19th. One analyst has rated the stock with a sell rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Aclaris Therapeutics has an average rating of “Buy” and an average price target of $11.00.

Aclaris Therapeutics Price Performance

Aclaris Therapeutics stock opened at $2.57 on Thursday. The firm has a market capitalization of $183.58 million, a price-to-earnings ratio of -4.94 and a beta of 0.50. The company’s 50 day simple moving average is $2.90 and its 200 day simple moving average is $2.04. Aclaris Therapeutics has a fifty-two week low of $0.95 and a fifty-two week high of $5.17.

Insider Buying and Selling at Aclaris Therapeutics

In other news, Director Anand Mehra acquired 666,666 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The stock was bought at an average price of $2.25 per share, with a total value of $1,499,998.50. Following the transaction, the director now directly owns 710,030 shares in the company, valued at approximately $1,597,567.50. The trade was a 1,537.37 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 6.40% of the company’s stock.

Institutional Trading of Aclaris Therapeutics

A number of hedge funds have recently made changes to their positions in ACRS. BML Capital Management LLC lifted its holdings in Aclaris Therapeutics by 9.7% during the 3rd quarter. BML Capital Management LLC now owns 14,250,000 shares of the biotechnology company’s stock valued at $16,388,000 after purchasing an additional 1,261,866 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in shares of Aclaris Therapeutics in the third quarter valued at about $1,053,000. Stonepine Capital Management LLC raised its position in shares of Aclaris Therapeutics by 27.6% in the third quarter. Stonepine Capital Management LLC now owns 2,458,873 shares of the biotechnology company’s stock valued at $2,828,000 after purchasing an additional 531,427 shares during the period. Peapod Lane Capital LLC acquired a new stake in shares of Aclaris Therapeutics during the 4th quarter worth about $1,003,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Aclaris Therapeutics by 187.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 332,406 shares of the biotechnology company’s stock worth $382,000 after buying an additional 216,826 shares during the period. 98.34% of the stock is owned by institutional investors and hedge funds.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.